Analyst: Oral semaglutide shows weight-loss effect similar to Wegovy
Drugmaker Novo Nordisk might soon have a palette of obesity treatments, assesses an analyst at investment bank Sydbank.
by marketwire, translated by daniel pedersen
On Monday, Novo Nordisk presented headline results from a phase IIIa with oral semaglutide in a 50mg dose – and analyst at Danish investment bank Sydbank Søren Løntoft Hansen assesses that obesity treatment effects were not unlike that of sister drug, Wegovy, which is based on the same active ingredient.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk to submit obesity tablet for approval this year
For subscribers
